UPCC 06419: Phase 1/2 Open Label Multi-center Dose-Escalation

Recruiting

99 years or below

All

Phase 1

1 Location

Brief description of study

This is a Phase 1/2, open-label, multicenter dose-escalation and dose-expansion trial evaluating the safety and tolerability of fimepinostat administered orally to patients with R/R lymphoma.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: lymphoma
Age: 99 years or below
Gender: All

Updated on 19 Feb 2024. Study ID: 832894

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

UPCC 06419: Phase 1/2 Open Label Multi-center Dose-Escalation Study to Assess the Safety Tolerability and Pharmacokinetics of Orally Administered Fimepinostat (CUDC-907) a PI3K and HDAC Inhibitor in Subjects with Relapsed and/or Refractory Lymphoma

Brief description of study

Eligibility of study

Find a site